Astrotech Q2 FY2023: $46.8M cash, YTD rev $301K, gross margin 38%, new products, $1M buyback

ASTROTECH Corp

YTD revenue $301K (6mo ended Dec 31, 2022); gross margin improved to 38% from 18% YoY.
Cash and liquid investments $46.8M; board authorized $1M share repurchase program on Nov 17, 2022.
Launched AgLAB 1000-D2 and D2-MVP control system; claims up to 45% improvement in yields and revenues.
BreathTest-1000 can distinguish infected vs healthy breath samples; collecting data for FDA approval.
Appointed Bob McFarland to board Jan 27, 2023; completed reverse stock split to regain Nasdaq compliance.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ASTROTECH Corp reported second quarter of fiscal year 2023, which ended December 31, 2022 results: revenue Year-to-date revenue totaled $301 thousand.

Period: second quarter of fiscal year 2023, which ended December 31, 2022
Revenue: Year-to-date revenue totaled $301 thousand
Result: reported results

Exact text from the filing

Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for its second quarter of fiscal year 2023, which ended December 31, 2022. Financial Highlights & Recent Developments ● Astrotech’s consolidated balance sheet remains strong with $46.8 million in cash and liquid investments. ● Year-to-date revenue totaled $301 thousand

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

ASTROTECH Corp filing history →

Source: SEC EDGAR

accession 0001437749-23-003085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.